5326372025-10-012025-12-315326372025-04-012025-12-315326372025-10-012025-12-31in-capmkt:OtherExpenses1Member5326372025-04-012025-12-31in-capmkt:OtherExpenses1Member5326372025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15326372025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15326372025-10-012025-12-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532637MANGALAMNOTLISTEDINE584F01014MANGALAM DRUGS AND ORGANICS LIMITEDMain BoardEquity2025-04-012026-03-312026-01-152026-01-07INRLakhsQuarterlyThird quarterSingle segmentManufacturing of Bulk Drugs2026-01-1512:00:002026-01-1514:30:00Declaration of unmodified opinion2025-10-012025-12-31UnauditedConsolidated58487500011080005859830003706120000133000838620004053100044610000144585000684333000-983500000-983500005000050000-983550000000-983550000-9835500015828200010-6.21-6.2100-6.21-6.211.The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the Companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter. <BR> <BR> 2.The above unaudited standalone financial results of the Company for the Quarter and Nine Months ended have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company (Mangalam Drugs and Organics Limited) at their meeting held on January 15,2026. Statutory auditors have carried Limited Review for the quarter and nine months ended on that date. <BR> <BR> 3.The Company's business activity falls within a single reportable Business Segment Viz. “Manufacturing of Bulk Drugs”. <BR> <BR> 4.The figures for the quarter ended 31st December, 2025 are the balancing figures between the figures in respect of nine months ended 31st December, 2025 and the unaudited published figures for the half year ended 30th September 2025. <BR> <BR> 5.Consolidated results include results of Mangalam Laboratories Private Limited, subsidiary for the purpose of Consolidated results. <BR> <BR> 6.Mangalam Laboratories Private Limited is a wholly owned subsidiary of the Company. The Wholly owned Subsidiary is not a material subsidiary of the Company. <BR> <BR> 7.The Board of Directors of the Company at its meeting held on March 15, 2024 had considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Private Limited ("First Transferor Company") and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ("Second Transferor Company") with Mangalam Drugs and Organics Limited ("Transferee Company") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to approval of Hon’ble National Company Law Tribunal. The final hearing for the same is scheduled on 10th March, 2026. <BR> <BR> 8.The Government of India has consolidated Twenty-Nine existing labour legislation into a united framework comprising four labour Codes viz. Code on Wages 2019, Code on Social Security 2020, Industrial relation Code 2020 and Occupational Safety Health and Working condition Code 2020 (collectively referred to as ‘New Labour Codes’). These Codes have been made effective from 21st November 2025. The corresponding all supporting rules under these Codes are yet to be notified. The Company is in process of evaluating full impact of these New Labour Codes. The impact due to these Codes will be examined as on 31st March 2026. <BR> <BR> 9.Other Expenses <BR> <BR> Rs in Lakhs <BR> Particulars Quarter Ended Nine Months Ended Year Ended <BR> 31.12.2025 30.09.2025 31.12.2024 31.12.2025 31.12.2024 31.03.2025 <BR> Unaudited Unaudited Unaudited Unaudited Unaudited Audited <BR> Power and <BR> Fuel Expenses 505.41 437.32 672.39 1,389.17 2,125.93 2,788.76 <BR> Pollution Contro <BR> Expenses 184.83 89.97 182.81 443.10 631.84 901.14 <BR> Advertisement <BR> & Sales Promotion 187.81 36.54 75.48 260.56 119.47 159.46 <BR> <BR> 10. The figures for the previous peridos have been regrouped wherever necessary to confirm to the current periods classification. <BR> <BR> <BR> 10.The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods classification. <BR> 2025-04-012025-12-31UnauditedConsolidated165380300013900001655193000892800000140002043180002530010001312590001356530003911480002008193000-3530000000-3530000002881000-46080000-431990000-3098010000000-309801000-2600000-31240100015828200010-19.57-19.5700-19.57-19.57Other Expenses144585000Other Expenses391148000Other comprehensive income [Abstract]00Other comprehensive income [Abstract]-2600000-260000000000-2600000UnauditedtrueM/s.V . S. SOMANI & CO.true2027-07-31